Sino Biopharm Shares Sink 14% in Hong Kong After Earnings Shock
5 years ago 1 min read
Chinese drugmaker Sino Biopharmaceutical Ltd. plunged by as much as 14% in Hong Kong after its third-quarter earnings missed expectations, partly due to the impact of a centralized drug procurement program on prices.
More Stories
Record Korean Cases; Trader’s Guide to Rollout: Virus Update
California Hits Record; Trader’s Guide to Rollout: Virus Update
AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push